POSTER SESSION III Tuesday, March 9, 2004   —  9:30 AM - 12:00 Noon Exhibit Hall B and C HEMATOPATHOLOGY 111 p53 Gene Alterations and Expression in Anaplastic Large Cell Lymphoma (ALCL) (1118) GZ Rassidakis, R Lai, A Thomaides, S Wang, Y Jiang, LJ Medeiros - The University of Texas MD Anderson Cancer Center, Houston, TX 112 C-Kit Is Not Expressed in Hodgkin's Disease and Is Rarely Expressed in Anaplastic Large Cell Lymphoma (1117) GZ Rassidakis, GV Georgakis, A Younes, LJ Medeiros - The University of Texas MD Anderson Cancer Center, Houston, TX 113 Activation of Intrinsic Apoptotic Pathway in an Aplastic Large Cell Lymphoma (1111) MP Oyarzo, LJ Medeiros, M Feretzaki, HM Amin, GZ Rassidakis - The University of Texas M.D. Anderson Cancer Center, Houston, TX 114 STAT3 Activation Contributes to High TIMP1 Expression in ALK-Positive Anaplastic Large Cell Lymphoma (1002) HM Amin, GZ Rassidakis, LJ Medeiros, L Ramdas, AH Goy, Y Fujio, K Kunisada, F Giles, R Lai - The University of Texas MD Anderson Cancer Center, Houston, TX; Graduate School of Medicine, Osaka, Japan 115 Microarray Analysis Demonstrates Differences in the Pathogenesis of ALK+ and ALK- Anaplastic Large Cell Lymphomas (1043) JR Frump, SE Henrickson, A Rosenwald, Q Wang, SJ Olson, KS Hamilton, L Staudt, MC Kinney, MA Thompson - Vanderbilt University Medical Center, Nashville, TN; National Cancer Institute, NIH, Bethesda, MD; University of Texas Health Science Center at San Antonio, San Antonio, TX 116 Primary Bone Anaplastic Large Cell Lymphoma (ALCL) in Pediatric Age Group (1006) NA Bakshi, CW Ross, WG Finn, R Valdez, R Ruiz, B Schnitzer - University of Michigan, Ann Arbor, MI 117 Fascin Expression in Diffuse Large B-Cell Lymphoma (DLBCL), Anaplastic Large Cell Lymphoma (ALCL) and Classical Hodgkin Lymphoma (CHL) (1007) NA Bakshi, WG Finn, R Valdez, CW Ross, B Schnitzer - University of Michigan, Ann Arbor, MI 118 Morphologic, Immunphenotypic and Clinical Discriminators between T-Cell Histiocyte Rich Large B Cell Lymphoma (TCHRLBCL) and Lymphocyte Predominent Hodgkin Lymphoma (LPHL) (1103) WA Mourad, SA Thani, Y Khafaga, M Shoukri, ME Shabana, A Ezzat - King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia 119 Four Color Flow Cytometric Analysis of Plasma Cells as Criteria for Diagnosis of Multiple Myeloma (1143) V Sundararajan, TT Cho, S Sylvest, C Alvares, PE Hurtubise - University of Cincinnati College of Medicine, Cincinnati, OH 120 Chromosome Abnormalities and Its Associations in Plasma Cell Myeloma (1133) F Sen, M Perle, S Ibrahim, C Liu, A Mazumder, S Jaganath, A Goldenberg, G Inghirami - New York University, New York, NY; St. Vincent Cancer Center, New York, NY 121 Dysregulation of Paracrine CD40 Signaling Mediates Primary Myeloma Cell Survival in the Bone Marrow Microenvironment (1058) E Hatada, S Ely, R Niesvizky, M Moore, S Chen-Kiang - Weill Medical College of Cornell University, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY 122 Correlation of PAX-5 Expression with Other Immunophenotypic Markers in Plasma Cell Neoplasia (1051) W Gorczyca, Z Liu, H Dong, J Weisberger - Impath, New York, NY 123 Cytogenetic Abnormalities in Histologically Confirmed Multiple Myeloma (1015) M Bonnett, JA Zonder, AN Mohamed, G Bentley - Wayne State University & Karmanos Cancer Institute, Detroit, MI 124 Proliferation and Apoptotic Markers in Multiple Myeloma (1093) G McKenzie, S Mathew, G Tricot, C Lee, L Joseph - University of Arkansas for Medical Sciences, Little Rock, AR 125 Comparison of Syndecan-1 (CD-138), PAS, and H&E Staining in Initial Evaluation of Monoclonal Gammopathies (1041) PE Ferguson, KK Oza, Y Ma - University of Arkansas for Medical Sciences, Little Rock, AR 126 The Pitfalls of Bone Marrow Aspirate Assessment of Plasma Cell Infiltrates (999) SZ Al-Quran, JM Magill, L Yang, RC Braylan, VK Douglas-Nikitin - University of Florida, College of Medicine, Gainesville, FL 127 Immunohistologic Comparison of VEGF Production in Bone Marrow Biopsies of POEMS and MGUS Patients (1095) DM Menke, H-P Horny, V Rajkumar, A Dispenzieri - Mayo Clinic, Jacksonville, FL; University of Luebeck, Lubeck, Germany; Mayo Clinic, Rochester, MN 128 Tissue Microarray Analysis of Bone Marrow Cores from Patients with Plasma Cell Leukemia, Multiple Myeloma, and MGUS Reveals Significant Differences in CD27 and CD56 Expression (1101) T Morgan, S Zhao, E Domanay, K Chang, PJ Cornbleet, DA Arber, Y Natkunam - Stanford University Medical Center, Stanford, CA; City of Hope, Duarte, CA 129 Plasma Cell Immaturity by Histology Does Not Correlate with Poor Prognostic Markers in Myeloma (1151) J Thomas, DP O'Malley, G Kong, MB Czader, A Orazi - Indiana University School of Medicine, Indianapolis, IN 130 CD20 and CD117 Expression Correlates with Plasma Cell Morphology in Plasma Cell Myeloma (1138) B Siddiqi, P Hari, DH Vesole, CC Chang, L Novoa-Takara, VB Shidaham, B Kampalath - Medical College of Wisconsin, Milwaukee, WI; Baylor College of Medicine, Houston, TX 131 Dkk-1 Expression in Normal Lymphoid Tissue and in Multiple Myelomas: Over Expression of Dkk-1 in Low and Medium Grade Myeloma with Loss of Expression with Disease Progression (1149) JW Theus, B Fender, J Waldron, F Zhan, J Shaughnessy, Y Ma - University of Arkansas for Medical Sciences, Little Rock, AR 132 Comparison of Ancillary Studies in Residual Disease of Plasma Cell Myeloma on Bone Marrow 1166 X Zhao, Q Huang, L Weiss - City of Hope National Medical Center, Duarte, CA